Trial Supports Earlier Use of a Prostate Cancer Drug - New York Times

In a small clinical trial, six months of treatment with the drug, Johnson & Johnson’s Zytiga, added to standard therapy, eliminated or nearly eliminated tumors in about one-third of men whose disease had not yet spread beyond the prostate ...

Prostate Cancer Drug Zytiga Proves Effective in Trials - HealthCentral.com

A new drug may offer another treatment option to men with advanced stages of prostate cancer. While early-stage cancers can be monitored, but not necessarily acted on, advanced versions often require an invasive procedure, either through surgery or radiation.

J&J's Zytiga may be useful in early prostate cancer, too - FiercePharma

Johnson & Johnson's ($JNJ) Zytiga is FDA-approved for men with advanced prostate cancer. But a new study suggests it may be effective in early-stage disease, too. The small trial--it involved only 58 patients with localized, high-risk cancer ...

J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK - NASDAQ

LONDON -(Dow Jones)- The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price ...

Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate) - Yahoo Finance

NEW BRUNSWICK, N.J., May 25, 2012 /PRNewswire/ -- Johnson & Johnson (JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time, to coincide with the ...

ZYTIGA® (abiraterone acetate) Data to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire

Note: This release corresponds to ASCO abstracts LBA 4518, 4521, 4556 and 4558. Data related to ZYTIGA ® (abiraterone acetate) clinical studies have been selected for presentation at the 48 th Annual Meeting of the American Society of Clinical Oncology ...

Study Shows J&J's Zytiga Can Eliminate Some Prostate Tumors; Drug Combinations Show Promise - Wall Street Journal

WASHINGTON (Dow Jones)--A study looking at small group of men with prostate cancer showed the use of Johnson & Johnson's (JNJ) Zytiga eliminated or greatly reduced the size of prostate tumors in one-third of patients treated for six months ...

Advanced Prostate Cancer Drug May Help at Earlier Stage - YAHOO!

Adding Zytiga (abiraterone) to conventional hormonal treatments eliminated or nearly eliminated the prostate cancer in one-third of men with this often-lethal form, according to new research to be presented at next month's annual meeting of the American ...

Dendreon Declines as J&J Rival to Provenge Shows Benefits - Bloomberg

Dendreon Corp. (DNDN), maker of the prostate cancer drug Provenge, dropped to its lowest value in four months after Johnson & Johnson (JNJ)’s rival medicine Zytiga helped high-risk patients in a study. Dendreon fell 11 percent to $7.65 at the ...

Dendreon's Saving Grace - Motley Fool

There was also a disclosure of an SEC investigation about its lowered guidance, but that seems to be a lesser concern than J&J's Zytiga stealing all of its potential customers away. The data is from the American Society of Clinical Oncology ...